F S&P 500
5,243.50 -2.75 (-0.05%) F Dow Jones
39,627.00 -15.00 (-0.04%) F Nasdaq
18,252.00 -3.00 (-0.02%) E-mini Russell 2000 Index Futur
2,067.50 -0.40 (-0.02%) Petróleo
78.06 -0.20 (-0.26%) Oro
2,367.40 -7.60 (-0.32%)
Ipsen S.A. (IPSEF)
Ipsen S.A.
65, quai Georges Gorse
Boulogne-Billancourt 92100
France
33 1 58 33 50 00
https://www.ipsen.com
Sector(es): Healthcare
Industria: Drug Manufacturers - Specialty & Generic
Empleados a tiempo completo: 5,325
Ejecutivos clave
| Nombre | Título | Pagar | Ejecutado | Año de nacimiento |
|---|---|---|---|---|
| Mr. David Loew | MD, CEO & Director | 2.28M | N/D | 1967 |
| Mr. Aymeric Le Chatelier | Executive VP & CFO | 788.8k | N/D | 1969 |
| Dr. Aidan Murphy Ph.D. | Executive VP and Head of Technical Operations | N/D | N/D | 1966 |
| Mr. Craig Marks | Vice-President of Investor Relations | N/D | N/D | N/D |
| Mr. Francois Garnier | Executive VP of Legal Affairs, General Counsel & Chief Business Ethics Officer | N/D | N/D | 1962 |
| Ms. Gwenan White | Executive VP and Head of Communications, Public Affairs & Sustainability | N/D | N/D | N/D |
| Mr. Regis Mulot | Executive VP & Chief Human Resources Officer | N/D | N/D | 1966 |
| Ms. Dominique Bery | Head of Nordics & Baltics | N/D | N/D | 1971 |
| Mr. Bartosz Bednarz D.D.S. | Executive VP and Head of Global Product & Portfolio Strategy | N/D | N/D | N/D |
| Mr. Philippe Lopes-Fernandes CBO | Executive VP & Chief Business Officer | N/D | N/D | N/D |
Descripción
Ipsen S.A. operates as a biopharmaceutical company worldwide. The company provides drugs in the areas of oncology, neuroscience, and rare diseases. Its product pipeline comprises Cabometyx + Atezolizumab, which is in phase III clinical trial for the treatment of second line metastatic castration-resistant prostate cancer; lenalidomide and rituximab, and Taverik, which is in phase III for the treatment of second line follicular lymphoma; Bylvay, which is in phase III for the treatment of biliary atresia; Dysport, which is in phase III clinical trial for the treatment of chronic and episodic migraine; Fidrisertib, which is in phase II clinical trial for the treatment of fibrodysplasia ossificans progressiva; Elafibranor, which is in phase II for the treatment of primary sclerosing cholangitis, as well as IPN60250; IPN10200, which is in phase II for the treatment of longer-acting neurotoxin aesthetics and therapeutics; IPN60210, which is in phase I clinical trial for the treatment of relapsed/refractory multiple myeloma; and IPN60260 for the treatment of Viral cholestatic disease and is in phase I clinical trial. The company also offers Somatuline, Decapeptyl, Cabometyx, Onivyde, Tazverik, and other oncology products; Dysport and other neurosciences products; and Bylvay, NutropinAq, Increlex, and Sohonos for rare diseases. The company was founded in 1929 and is based in Boulogne-Billancourt, France.
Gestión corporativa
La calificación ISS Governance QuickScore de Ipsen S.A. a partir del 1 de mayo de 2024 es 8. Las puntuaciones principales son Auditoría: 8; Junta: 7; Derechos del accionista: 7; Compensación: 7.
